Home > Boards > US Listed > Biotechs > Biohaven Pharmceuticals (BHVN)

PTGEF is undervalued big time. BHVN surged again.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
ronpopeil Member Profile
Member Level 
Followed By 114
Posts 8,746
Boards Moderated 1
Alias Born 10/05/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/17/2019 6:30:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/3/2019 7:09:13 AM
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts Genera... PR Newswire (US) - 9/18/2019 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2019 4:35:33 PM
Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The ... PR Newswire (US) - 9/10/2019 7:30:00 AM
Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes Af... PR Newswire (US) - 9/9/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 7:25:25 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/21/2019 4:12:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/19/2019 6:42:33 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/9/2019 4:44:24 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 4:33:12 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 4:17:28 PM
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments PR Newswire (US) - 8/9/2019 6:47:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/8/2019 5:09:13 PM
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments PR Newswire (US) - 8/8/2019 5:02:00 PM
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial PR Newswire (US) - 8/7/2019 7:30:00 AM
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment O... PR Newswire (US) - 7/31/2019 7:30:00 AM
Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled PR Newswire (US) - 7/22/2019 7:30:00 AM
Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in... PR Newswire (US) - 7/15/2019 7:30:00 AM
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Ne... PR Newswire (US) - 7/11/2019 7:30:00 AM
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headach... PR Newswire (US) - 7/11/2019 7:30:00 AM
Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine PR Newswire (US) - 7/10/2019 5:00:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 4:27:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 5:37:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 5:36:11 PM
ronpopeil Member Level  Wednesday, 05/10/17 04:09:16 PM
Re: nohypeneeded post# 2
Post # of 12 
PTGEF is undervalued big time. BHVN surged again. PTGEF should be much higher based on their 6+ million share ownership of BHVN. That doesn't even factor in their ownership in other promising companies

"Don't worry about the world coming to an end today. It's already tomorrow in Australia"

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist